NGM Biopharmaceuticals Q2 EPS $(0.46) Beats $(0.50) Estimate, Sales $1.42M Miss $3.30M Estimate
Portfolio Pulse from Benzinga Newsdesk
NGM Biopharmaceuticals reported Q2 losses of $(0.46) per share, beating the analyst consensus estimate of $(0.50) by 8 percent. However, the company's quarterly sales of $1.42 million missed the analyst consensus estimate of $3.30 million by 56.88 percent, marking a 82.84 percent decrease from the same period last year.
August 04, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NGM Biopharmaceuticals reported better than expected Q2 EPS but significantly missed sales estimates. This could lead to mixed investor sentiment.
NGM Biopharmaceuticals reported a better than expected EPS for Q2, which is a positive signal for investors. However, the company significantly missed sales estimates, which could negatively impact investor sentiment. The net effect could be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100